Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

Corrigendum: An Overview of MicroRNAs as Biomarkers of ALS.

Joilin G, Leigh PN, Newbury SF, Hafezparast M.

Front Neurol. 2019 Oct 23;10:1129. doi: 10.3389/fneur.2019.01129. eCollection 2019.

2.

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.

Al-Chalabi A, Shaw P, Leigh PN, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamäki M.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1165-1170. doi: 10.1136/jnnp-2018-320288. Epub 2019 Jul 17.

3.

Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials.

van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, Leigh PN, Al-Chalabi A, Eijkemans MJC, van den Berg LH.

J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1331-1337. doi: 10.1136/jnnp-2019-320998. Epub 2019 Jul 10.

4.

Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy.

Chen Z, Chen JA, Shatunov A, Jones AR, Kravitz SN, Huang AY, Lawrence L, Lowe JK, Lewis CM, Payan CAM, Lieb W, Franke A, Deloukas P, Amouyel P, Tzourio C, Dartigues JF; NNIPPS and BBBIPPS Study Groups, Ludolph A, Bensimon G, Leigh PN, Bronstein JM, Coppola G, Geschwind DH, Al-Chalabi A.

Mov Disord. 2019 Jul;34(7):1049-1059. doi: 10.1002/mds.27702. Epub 2019 May 6.

PMID:
31059154
5.

Predicting the future of ALS: the impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020-2116.

Gowland A, Opie-Martin S, Scott KM, Jones AR, Mehta PR, Batts CJ, Ellis CM, Leigh PN, Shaw CE, Sreedharan J, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):264-274. doi: 10.1080/21678421.2019.1587629. Epub 2019 Apr 9.

6.

An Overview of MicroRNAs as Biomarkers of ALS.

Joilin G, Leigh PN, Newbury SF, Hafezparast M.

Front Neurol. 2019 Mar 7;10:186. doi: 10.3389/fneur.2019.00186. eCollection 2019. Review. Erratum in: Front Neurol. 2019 Oct 23;10:1129.

7.

Relative preservation of triceps over biceps strength in upper limb-onset ALS: the 'split elbow'.

Khalaf R, Martin S, Ellis C, Burman R, Sreedharan J, Shaw C, Leigh PN, Turner MR, Al-Chalabi A.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):730-733. doi: 10.1136/jnnp-2018-319894. Epub 2019 Mar 7.

8.

Emerging Magnetic Resonance Imaging Techniques and Analysis Methods in Amyotrophic Lateral Sclerosis.

Barritt AW, Gabel MC, Cercignani M, Leigh PN.

Front Neurol. 2018 Dec 4;9:1065. doi: 10.3389/fneur.2018.01065. eCollection 2018. Review.

9.

Neurite orientation and dispersion density imaging (NODDI) detects cortical and corticospinal tract degeneration in ALS.

Broad RJ, Gabel MC, Dowell NG, Schwartzman DJ, Seth AK, Zhang H, Alexander DC, Cercignani M, Leigh PN.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):404-411. doi: 10.1136/jnnp-2018-318830. Epub 2018 Oct 25.

10.

Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases.

Chen JA, Chen Z, Won H, Huang AY, Lowe JK, Wojta K, Yokoyama JS, Bensimon G, Leigh PN, Payan C, Shatunov A, Jones AR, Lewis CM, Deloukas P, Amouyel P, Tzourio C, Dartigues JF, Ludolph A, Boxer AL, Bronstein JM, Al-Chalabi A, Geschwind DH, Coppola G.

Mol Neurodegener. 2018 Aug 8;13(1):41. doi: 10.1186/s13024-018-0270-8.

11.

Stage of prolonged survival in ALS - Author's reply.

Al-Chalabi A, Fang T, Khleifat AA, Meurgey JH, Jones A, Leigh PN, Bensimon G.

Lancet Neurol. 2018 Jul;17(7):579-580. doi: 10.1016/S1474-4422(18)30208-4. No abstract available.

PMID:
29914702
12.

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.

Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A.

Lancet Neurol. 2018 May;17(5):416-422. doi: 10.1016/S1474-4422(18)30054-1. Epub 2018 Mar 7.

13.

Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.

van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, Young CA, Shaw CE, Mora G, Mandrioli J, Borghero G, Volanti P, Diekstra FP, van Rheenen W, Verstraete E, Eijkemans MJC, Veldink JH, Chio A, Al-Chalabi A, van den Berg LH, van Es MA; For UKMND-LiCALS and LITALS Study Group.

Neurology. 2017 Oct 31;89(18):1915-1922. doi: 10.1212/WNL.0000000000004606. Epub 2017 Oct 4. Review. Erratum in: Neurology. 2017 Nov 28;89(22):2303.

14.

Late-onset Tay-Sachs disease.

Barritt AW, Anderson SJ, Leigh PN, Ridha BH.

Pract Neurol. 2017 Oct;17(5):396-399. doi: 10.1136/practneurol-2017-001665. Epub 2017 Jul 24.

PMID:
28739864
15.

The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.

Martin S, Trevor-Jones E, Khan S, Shaw K, Marchment D, Kulka A, Ellis CE, Burman R, Turner MR, Carroll L, Mursaleen L, Leigh PN, Shaw CE, Pearce N, Stahl D, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):569-575. doi: 10.1080/21678421.2017.1349151. Epub 2017 Jul 18.

16.

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.

Glasmacher SA, Leigh PN, Saha RA.

J Neurol Neurosurg Psychiatry. 2017 May;88(5):402-411. doi: 10.1136/jnnp-2016-314956. Epub 2017 Mar 1. Review.

PMID:
28250027
17.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group.

Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28.

18.

Comparison of the King's and MiToS staging systems for ALS.

Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C; Uk-Mnd LicalS, Young C, Shaw PJ, Leigh PN, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):227-232. doi: 10.1080/21678421.2016.1265565. Epub 2017 Jan 5.

19.

Characterizing axonal myelination within the healthy population: a tract-by-tract mapping of effects of age and gender on the fiber g-ratio.

Cercignani M, Giulietti G, Dowell NG, Gabel M, Broad R, Leigh PN, Harrison NA, Bozzali M.

Neurobiol Aging. 2017 Jan;49:109-118. doi: 10.1016/j.neurobiolaging.2016.09.016. Epub 2016 Sep 30.

20.

Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis.

Gaastra B, Shatunov A, Pulit S, Jones AR, Sproviero W, Gillett A, Chen Z, Kirby J, Fogh I, Powell JF, Leigh PN, Morrison KE, Shaw PJ, Shaw CE, van den Berg LH, Veldink JH, Lewis CM, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):593-599. Epub 2016 Sep 1.

21.

Respiratory Muscle Strength as a Predictive Biomarker for Survival in Amyotrophic Lateral Sclerosis.

Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):86-95. doi: 10.1164/rccm.201604-0848OC.

22.

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.

van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, Võsa U, de Jong S, Robinson MR, Yang J, Fogh I, van Doormaal PT, Tazelaar GH, Koppers M, Blokhuis AM, Sproviero W, Jones AR, Kenna KP, van Eijk KR, Harschnitz O, Schellevis RD, Brands WJ, Medic J, Menelaou A, Vajda A, Ticozzi N, Lin K, Rogelj B, Vrabec K, Ravnik-Glavač M, Koritnik B, Zidar J, Leonardis L, Grošelj LD, Millecamps S, Salachas F, Meininger V, de Carvalho M, Pinto S, Mora JS, Rojas-García R, Polak M, Chandran S, Colville S, Swingler R, Morrison KE, Shaw PJ, Hardy J, Orrell RW, Pittman A, Sidle K, Fratta P, Malaspina A, Topp S, Petri S, Abdulla S, Drepper C, Sendtner M, Meyer T, Ophoff RA, Staats KA, Wiedau-Pazos M, Lomen-Hoerth C, Van Deerlin VM, Trojanowski JQ, Elman L, McCluskey L, Basak AN, Tunca C, Hamzeiy H, Parman Y, Meitinger T, Lichtner P, Radivojkov-Blagojevic M, Andres CR, Maurel C, Bensimon G, Landwehrmeyer B, Brice A, Payan CA, Saker-Delye S, Dürr A, Wood NW, Tittmann L, Lieb W, Franke A, Rietschel M, Cichon S, Nöthen MM, Amouyel P, Tzourio C, Dartigues JF, Uitterlinden AG, Rivadeneira F, Estrada K, Hofman A, Curtis C, Blauw HM, van der Kooi AJ, de Visser M, Goris A, Weber M, Shaw CE, Smith BN, Pansarasa O, Cereda C, Del Bo R, Comi GP, D'Alfonso S, Bertolin C, Sorarù G, Mazzini L, Pensato V, Gellera C, Tiloca C, Ratti A, Calvo A, Moglia C, Brunetti M, Arcuti S, Capozzo R, Zecca C, Lunetta C, Penco S, Riva N, Padovani A, Filosto M, Muller B, Stuit RJ; PARALS Registry; SLALOM Group; SLAP Registry; FALS Sequencing Consortium; SLAGEN Consortium; NNIPPS Study Group, Blair I, Zhang K, McCann EP, Fifita JA, Nicholson GA, Rowe DB, Pamphlett R, Kiernan MC, Grosskreutz J, Witte OW, Ringer T, Prell T, Stubendorff B, Kurth I, Hübner CA, Leigh PN, Casale F, Chio A, Beghi E, Pupillo E, Tortelli R, Logroscino G, Powell J, Ludolph AC, Weishaupt JH, Robberecht W, Van Damme P, Franke L, Pers TH, Brown RH, Glass JD, Landers JE, Hardiman O, Andersen PM, Corcia P, Vourc'h P, Silani V, Wray NR, Visscher PM, de Bakker PI, van Es MA, Pasterkamp RJ, Lewis CM, Breen G, Al-Chalabi A, van den Berg LH, Veldink JH.

Nat Genet. 2016 Sep;48(9):1043-8. doi: 10.1038/ng.3622. Epub 2016 Jul 25.

23.

NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.

Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, van Rheenen W, van Eijk KR, Jones AR, Keagle P, Shatunov A, Sproviero W, Smith BN, van Es MA, Topp SD, Kenna A, Miller JW, Fallini C, Tiloca C, McLaughlin RL, Vance C, Troakes C, Colombrita C, Mora G, Calvo A, Verde F, Al-Sarraj S, King A, Calini D, de Belleroche J, Baas F, van der Kooi AJ, de Visser M, Ten Asbroek AL, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Muñoz-Blanco JL, Strom TM, Meitinger T, Morrison KE; SLAGEN Consortium, Lauria G, Williams KL, Leigh PN, Nicholson GA, Blair IP, Leblond CS, Dion PA, Rouleau GA, Pall H, Shaw PJ, Turner MR, Talbot K, Taroni F, Boylan KB, Van Blitterswijk M, Rademakers R, Esteban-Pérez J, García-Redondo A, Van Damme P, Robberecht W, Chio A, Gellera C, Drepper C, Sendtner M, Ratti A, Glass JD, Mora JS, Basak NA, Hardiman O, Ludolph AC, Andersen PM, Weishaupt JH, Brown RH Jr, Al-Chalabi A, Silani V, Shaw CE, van den Berg LH, Veldink JH, Landers JE.

Nat Genet. 2016 Sep;48(9):1037-42. doi: 10.1038/ng.3626. Epub 2016 Jul 25.

24.

A clinical tool for predicting survival in ALS.

Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, Tsuda M, Al-Chalabi A.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1361-1367. doi: 10.1136/jnnp-2015-312908. Epub 2016 Jul 4.

25.

Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis.

Fogh I, Lin K, Tiloca C, Rooney J, Gellera C, Diekstra FP, Ratti A, Shatunov A, van Es MA, Proitsi P, Jones A, Sproviero W, Chiò A, McLaughlin RL, Sorarù G, Corrado L, Stahl D, Del Bo R, Cereda C, Castellotti B, Glass JD, Newhouse S, Dobson R, Smith BN, Topp S, van Rheenen W, Meininger V, Melki J, Morrison KE, Shaw PJ, Leigh PN, Andersen PM, Comi GP, Ticozzi N, Mazzini L, D'Alfonso S, Traynor BJ, Van Damme P, Robberecht W, Brown RH, Landers JE, Hardiman O, Lewis CM, van den Berg LH, Shaw CE, Veldink JH, Silani V, Al-Chalabi A, Powell J.

JAMA Neurol. 2016 Jul 1;73(7):812-20. doi: 10.1001/jamaneurol.2016.1114.

26.

Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease.

Rutter-Locher Z, Turner MR, Leigh PN, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):600-604. Epub 2016 May 18.

PMID:
27188215
27.

Syntactic processing as a marker for cognitive impairment in amyotrophic lateral sclerosis.

Tsermentseli S, Leigh PN, Taylor LJ, Radunovic A, Catani M, Goldstein LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1-2):69-76. doi: 10.3109/21678421.2015.1071397. Epub 2015 Aug 24.

28.

Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.

van der Kleij LA, Jones AR, Steen IN, Young CA, Shaw PJ, Shaw CE, Leigh PN, Turner MR, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):442-7. doi: 10.3109/21678421.2015.1051987. Epub 2015 Jun 17.

PMID:
26083873
29.

Recognising facial onset sensory motor neuronopathy syndrome: insight from six new cases.

Broad R, Leigh PN.

Pract Neurol. 2015 Aug;15(4):293-7. doi: 10.1136/practneurol-2014-000984. Epub 2015 May 19.

PMID:
25991863
30.

Decision Making About Gastrostomy and Noninvasive Ventilation in Amyotrophic Lateral Sclerosis.

Martin NH, Lawrence V, Murray J, Janssen A, Higginson I, Lyall R, Burman R, Leigh PN, Al-Chalabi A, Goldstein LH.

Qual Health Res. 2016 Aug;26(10):1366-81. doi: 10.1177/1049732315583661. Epub 2015 Apr 27.

PMID:
25918114
31.

Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients' perspectives.

Greenaway LP, Martin NH, Lawrence V, Janssen A, Al-Chalabi A, Leigh PN, Goldstein LH.

J Neurol. 2015;262(4):1002-13. doi: 10.1007/s00415-015-7665-z. Epub 2015 Feb 17.

PMID:
25683760
32.

Impact commentaries. Subacute necrotising encephalomyelopathy (Leigh's disease; Leigh syndrome).

Leigh PN, Al-Sarraj S, DiMauro S.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):363-5. doi: 10.1136/jnnp-2012-304601. Epub 2015 Jan 13. No abstract available.

33.

Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study.

Al-Sarraj S, King A, Cleveland M, Pradat PF, Corse A, Rothstein JD, Leigh PN, Abila B, Bates S, Wurthner J, Meininger V.

Acta Neuropathol Commun. 2014 Dec 14;2:165. doi: 10.1186/s40478-014-0165-z.

34.

Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Worker A, Blain C, Jarosz J, Chaudhuri KR, Barker GJ, Williams SC, Brown R, Leigh PN, Simmons A.

PLoS One. 2014 Dec 2;9(12):e114167. doi: 10.1371/journal.pone.0114167. eCollection 2014.

35.

Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study.

Worker A, Blain C, Jarosz J, Chaudhuri KR, Barker GJ, Williams SC, Brown RG, Leigh PN, Dell'Acqua F, Simmons A.

PLoS One. 2014 Nov 18;9(11):e112638. doi: 10.1371/journal.pone.0112638. eCollection 2014.

36.

Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.

Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MHB, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N.

Lancet Neurol. 2014 Nov;13(11):1108-1113. doi: 10.1016/S1474-4422(14)70219-4. Epub 2014 Oct 7.

37.

C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis.

Diekstra FP, Van Deerlin VM, van Swieten JC, Al-Chalabi A, Ludolph AC, Weishaupt JH, Hardiman O, Landers JE, Brown RH Jr, van Es MA, Pasterkamp RJ, Koppers M, Andersen PM, Estrada K, Rivadeneira F, Hofman A, Uitterlinden AG, van Damme P, Melki J, Meininger V, Shatunov A, Shaw CE, Leigh PN, Shaw PJ, Morrison KE, Fogh I, Chiò A, Traynor BJ, Czell D, Weber M, Heutink P, de Bakker PI, Silani V, Robberecht W, van den Berg LH, Veldink JH.

Ann Neurol. 2014 Jul;76(1):120-33. doi: 10.1002/ana.24198. Epub 2014 Jun 27.

38.

Evidence of an environmental effect on survival in ALS.

Keren N, Scott KM, Tsuda M, Barnwell J, Knibb JA, Ellis CM, Leigh PN, Shaw CE, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):528-33. doi: 10.3109/21678421.2014.911326. Epub 2014 May 27.

PMID:
24862874
39.

Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.

Meininger V, Pradat PF, Corse A, Al-Sarraj S, Rix Brooks B, Caress JB, Cudkowicz M, Kolb SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J, Krull D, Berges A, Abila B, Meno-Tetang G, Wurthner J.

PLoS One. 2014 May 19;9(5):e97803. doi: 10.1371/journal.pone.0097803. eCollection 2014.

40.

Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.

Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):279-84. doi: 10.3109/21678421.2014.897357. Epub 2014 Apr 10.

PMID:
24720420
41.

Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.

Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, Young C, Shaw PJ, Leigh PN, Turner MR, Steen IN, McCrone P, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):285-91. doi: 10.3109/21678421.2013.872149. Epub 2014 Feb 7.

PMID:
24641613
42.

Psychological as well as illness factors influence acceptance of non-invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): a prospective population study.

Martin NH, Landau S, Janssen A, Lyall R, Higginson I, Burman R, McCrone P, Sakel M, Ellis CM, Shaw CE, Al-Chalabi A, Leigh PN, Goldstein LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):376-87. doi: 10.3109/21678421.2014.886700. Epub 2014 Mar 6.

PMID:
24597488
43.

Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials.

Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, Turner MR, Leigh PN, Al-Chalabi A; UK-MND LiCALS Study Group, Mito Target ALS Study Group.

J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):45-9. doi: 10.1136/jnnp-2013-306865. Epub 2014 Jan 24.

44.

Automated, high accuracy classification of Parkinsonian disorders: a pattern recognition approach.

Marquand AF, Filippone M, Ashburner J, Girolami M, Mourao-Miranda J, Barker GJ, Williams SC, Leigh PN, Blain CR.

PLoS One. 2013 Jul 15;8(7):e69237. doi: 10.1371/journal.pone.0069237. Print 2013.

45.

Behavioural and emotional symptoms of apathy are associated with distinct patterns of brain atrophy in neurodegenerative disorders.

Stanton BR, Leigh PN, Howard RJ, Barker GJ, Brown RG.

J Neurol. 2013 Oct;260(10):2481-90. doi: 10.1007/s00415-013-6989-9. Epub 2013 Jun 23.

PMID:
23793818
46.

Genetic and epigenetic studies of amyotrophic lateral sclerosis.

Al-Chalabi A, Kwak S, Mehler M, Rouleau G, Siddique T, Strong M, Leigh PN.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:44-52. doi: 10.3109/21678421.2013.778571. Review.

PMID:
23678879
47.

Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat.

Jones AR, Woollacott I, Shatunov A, Cooper-Knock J, Buchman V, Sproviero W, Smith B, Scott KM, Balendra R, Abel O, McGuffin P, Ellis CM, Shaw PJ, Morrison KE, Farmer A, Lewis CM, Leigh PN, Shaw CE, Powell JF, Al-Chalabi A.

Neurobiol Aging. 2013 Sep;34(9):2234.e1-7. doi: 10.1016/j.neurobiolaging.2013.03.003. Epub 2013 Apr 12.

48.

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.

UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, Kelly J, Murphy CL, Al-Chalabi A, Dougherty A, Leigh PN, Wijesekera L, Thornhill M, Ellis CM, O'Hanlon K, Panicker J, Pate L, Ray P, Wyatt L, Young CA, Copeland L, Ealing J, Hamdalla H, Leroi I, Murphy C, O'Keeffe F, Oughton E, Partington L, Paterson P, Rog D, Sathish A, Sexton D, Smith J, Vanek H, Dodds S, Williams TL, Steen IN, Clarke J, Eziefula C, Howard R, Orrell R, Sidle K, Sylvester R, Barrett W, Merritt C, Talbot K, Turner MR, Whatley C, Williams C, Williams J, Cosby C, Hanemann CO, Iman I, Philips C, Timings L, Crawford SE, Hewamadduma C, Hibberd R, Hollinger H, McDermott C, Mils G, Rafiq M, Shaw PJ, Taylor A, Waines E, Walsh T, Addison-Jones R, Birt J, Hare M, Majid T.

Lancet Neurol. 2013 Apr;12(4):339-45. doi: 10.1016/S1474-4422(13)70037-1. Epub 2013 Feb 27. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

49.

Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: a cross-sectional study of patients with Parkinson's disease and related neurological conditions.

Saleem TZ, Higginson IJ, Chaudhuri KR, Martin A, Burman R, Leigh PN.

Palliat Med. 2013 Sep;27(8):722-31. doi: 10.1177/0269216312465783. Epub 2012 Dec 3.

PMID:
23208011
50.

Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors.

Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, McCrone P, Leigh PN.

PLoS One. 2012;7(11):e46327. doi: 10.1371/journal.pone.0046327. Epub 2012 Nov 7.

Supplemental Content

Loading ...
Support Center